The Two Blood Tests Most People Over 55 Have Never Had — And the 2026 Guideline That Changed the Rules

You have had your cholesterol checked for thirty years. Total, LDL, HDL, triglycerides. The number at the bottom said "normal," your doctor said "keep doing what you're doing," and you went to lunch. In March 2026, the American College of Cardiology and the American Heart Association — with nine other medical organizations — retired the old cholesterol guideline and replaced it. Two tests that used to be considered specialty items are now part of the conversation. Most people over 55 have never had either one.

They are apolipoprotein B, usually written apoB, and lipoprotein(a), usually written Lp(a) and pronounced "L-P-little-a." Neither appears on the standard lipid panel your primary care office orders by default. Both can change how your risk is understood.

The new guideline recommends that lipoprotein(a) be measured at least once in all adults. If you have never had it done, that is a gap — not a personal failure.

What changed in 2026

The 2026 dyslipidemia guideline replaced the 2018 blood cholesterol guideline and widened the focus from LDL cholesterol alone to the whole family of artery-clogging particles, including triglycerides and Lp(a). Among the headline changes: universal lipid screening in adults beginning at age 19 and repeating roughly every five years, a new risk calculator (the PREVENT equations) that estimates both 10-year and 30-year risk, the return of specific treatment targets, and personalized risk discussions that may include coronary calcium scoring, apoB and Lp(a).

For a reader in their late fifties, sixties or seventies, the practical translation is short: the standard panel is the starting point, not the finish line.

Why LDL alone can mislead you

LDL cholesterol measures the amount of cholesterol being carried in your blood. ApoB measures how many particles are doing the carrying. Every atherogenic particle — the kind that lodges in artery walls — carries exactly one apoB molecule, so apoB is essentially a particle count.

That distinction matters because two people can have the same LDL number with very different particle counts. The person with more particles, each carrying a little less cholesterol, is walking around with more objects capable of getting stuck. This is one reason a "normal" LDL can sit alongside real risk, and it is especially common in people with diabetes, prediabetes, high triglycerides or extra weight around the middle.

Lp(a) is the one you inherit

Lp(a) is a particle you are largely born with. Levels are set mostly by genetics, they stay fairly stable through adult life, and diet and exercise barely move them. Elevated Lp(a) is associated with earlier heart attacks, strokes and narrowing of the aortic valve — and it travels in families quietly, because nobody was testing for it in 1985.

Because the level does not change much, you generally need the test once. That is the whole ask. One tube of blood, one time, and a number you and your family get to keep.

If yours is high, the current approach is not a special Lp(a) drug for most people — it is treating everything else more aggressively: LDL and apoB driven lower, blood pressure controlled, tobacco gone, and a serious conversation about whether your risk category just moved. Several Lp(a)-lowering therapies are in late-stage trials; none should be assumed available to you today. Ask your clinician what is actually approved when you have the conversation.

What to say at your next appointment

Doctors are not withholding these tests. Visits are short, the old guideline did not push for them, and nobody asks. Bring the request in writing and it usually takes thirty seconds.

1. "Has my lipoprotein(a) ever been measured?" If the answer is no, ask for it once.
2. "Can we add apoB to my next lipid panel?" Particularly worth asking if you have diabetes, prediabetes, high triglycerides, a family history of early heart disease, or an LDL that has always looked fine while other numbers drifted.
3. "What does my 30-year risk look like, not just my 10-year risk?" The new equations produce both. At 58 the 30-year number is the honest one.
4. "Would a coronary calcium scan add anything for me?" The guideline supports selective use — it is not for everyone, and it does involve a small radiation dose and usually an out-of-pocket cost.
5. "If these come back elevated, what specifically would we do differently?" Order a test only when the answer changes something.

Cost, coverage and the direct-to-consumer temptation

Both tests are ordinary blood draws, and both are widely available through standard labs. Coverage varies by plan and by the reason your clinician documents, so ask the office to check before the draw rather than after. Cash prices at consumer labs are often modest, and for Lp(a) — a once-in-a-lifetime measurement — some people simply pay for it.

Be more skeptical of the expensive panels marketed directly to consumers with dozens of biomarkers and a glossy dashboard. A result nobody helps you interpret is not health care; it is a PDF. If you buy a test outside your doctor's office, send the result to your doctor's office.

Ask what a test will change before you pay for it. That single question filters out most of the longevity industry.

The unglamorous part still matters most

The new guideline keeps lifestyle as the foundation — a heart-healthy eating pattern, regular physical activity, weight and blood pressure control, sleep, stress, no tobacco — and it explicitly does not recommend dietary supplements for lowering lipids. That last line is worth reading twice if you have a cabinet full of them. Statins remain first-line treatment when medication is warranted, with a longer list of non-statin options available when it is not enough or not tolerated.

None of this makes you a patient. It makes you the person in the room who knows which number is missing.

Sources

• American Heart Association: ACC/AHA issue updated guideline for managing lipids and cholesterol (March 13, 2026)
• American College of Cardiology — 2026 Guideline on the Management of Dyslipidemia, published in JACC and Circulation

This article is general information, not medical advice. Testing and treatment decisions belong to you and your clinician. Second Act 360 was not compensated by any laboratory, manufacturer or medical organization mentioned here.